$12.59
$0.08 (+0.68%)
$12.55Day Range$12.80
Key Statistics
Market Cap
$4.28B
Shares Outstanding
339.8M
Primary Exchange
XNAS
Currency
USD
Type
ADRC
IPO Date
Nov 13, 2024
Round Lot
100
Locale
US
Trading Data
Day Open
$12.73
Day High
$12.80
Day Low
$12.55
Volume
187.4K
VWAP
$12.63
Prev Close
$12.51
Transactions
--
Acc. Volume
--
About Telix Pharmaceuticals Limited American Depositary Shares
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Identifiers
- CIK
- 0002007191
- Composite FIGI
- BBG01N69K900
- Share Class FIGI
- BBG01N69K9Y3
- Ticker Root
- TLX
About Telix Pharmaceuticals Limited American Depositary Shares (TLX) Stock
Telix Pharmaceuticals Limited American Depositary Shares (TLX) closed the 2026-09-18 session at $12.59, up 0.68% versus the previous close (+0.08). The stock opened at $12.73 and traded between $12.55 and $12.80 during that session. Session trading volume was 187K shares. The volume-weighted average price (VWAP) is $12.63.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Telix Pharmaceuticals Limited American Depositary Shares has a market capitalization of $4.28 billion. TLX is listed on the XNAS exchange. The company employs approximately 1,184 people. The recorded listing date is 2024-11-13.
On this page you can find market TLX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors.